## Highlights of This Issue

### SPECIAL FEATURES

#### CCR Translations

2999  
**Serum Cholesterol and mTOR Inhibitors: Surrogate Biomarker or Epiphenomenon?**  
Daniel C. Cho and Michael B. Atkins  
*See article p. 3188*

#### CCR New Strategies

3002  
**New Strategies in Squamous Cell Carcinoma of the Lung: Identification of Tumor Drivers to Personalize Therapy**  
Kathryn A. Gold, Ignacio I. Wistuba, and Edward S. Kim

#### CCR Drug Updates

3008  
**Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis**  
John Mascarenhas and Ronald Hoffman

#### Molecular Pathways

3015  
**Molecular Pathways: Interferon/Stat1 Pathway: Role in the Tumor Resistance to Genotoxic Stress and Aggressive Growth**  
Nikolai N. Khodarev, Bernard Roizman, and Ralph R. Weichselbaum

#### Review

3022  
**The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature**  
Ronald J. deLeeuw, Sara E. Kost, Juzer A. Kakal, and Brad H. Nelson

---

### HUMAN CANCER BIOLOGY

3030  
**MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma**  
John S. Jarboe, Joshua C. Anderson, Christine W. Duarte, Tapan Mehta, Somaira Nowsheen, Patricia H. Hicks, Alexander C. Whitley, Timothy D. Rohrbach, Raymond O. McCubrey, Sherard Chiu, Tamara M. Burleson, James A. Bonner, G. Yancey Gillespie, Eddy S. Yang, and Christopher D. Willey

3042  
**Decreased Selenium-Binding Protein 1 Enhances Glutathione Peroxidase 1 Activity and Downregulates HIF-1α to Promote Hepatocellular Carcinoma Invasiveness**  
Cheng Huang, Guangyu Ding, Chengyu Gu, Jian Zhou, Ming Kuang, Yuan Ji, Yifeng He, Tadashi Kondo, and Jia Fan

3054  
**Microarray Analysis of Colorectal Cancer Stromal Tissue Reveals Upregulation of Two Oncogenic miRNA Clusters**  
Naohiro Nishida, Makoto Nagahara, Tetsuya Sato, Koshi Mimori, Tomoya Sudo, Fumiaki Tanaka, Kohei Shibata, Hideshi Ishii, Kenichi Sugihara, Yuichiro Dokai, and Masaki Mori

3071  
**Aberrant L1 Cell Adhesion Molecule Affects Tumor Behavior and Chemosensitivity in Anaplastic Thyroid Carcinoma**  
Koon Soon Kim, Jeong-Ki Min, Zhe Long Liang, Kyungmin Lee, Jung Uee Lee, Kwang-Hee Bae, Min Hee Lee, Seong Eun Lee, Min Jeong Ryu, Seoung Jung Kim, Yong Kyoung Kim, Min Jeong Choi, Young Suk Jo, Jin-Man Kim, and Minho Shong

3079  
**Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients**  
Elena Spinelli, Roberto Caporale, Francesca Buchi, Erico Masala, Antonella Gozzini, Alessandro Sanna, Francesca Sassolini, Ana Valencia, Alberto Best, and Valeria Santini
**CANCER THERAPY: PRECLINICAL**

**3090**

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

Harvey Wong, Laurent Vernillet, Amy Peterson, Joseph A. Ware, Lillian Lee, Jean-Francois Martini, Peiwen Yu, Congfen Li, Geoffrey Del Rosario, Edna F. Choo, Klaus P. Hoeflich, Yongchang Shi, Blake T. Altah, Ron Aoyama, Sanh Tan Lam, Marcia Belvin, and John Prescott

**3100**

Carbonic Anhydrase IX Promotes Tumor Growth and Necrosis In Vivo and Inhibition Enhances Anti-VEGF Therapy

Alan McIntyre, Shalini Patiar, Simon Wigfield, Ji-liang Li, Ioanna Ledaki, Helen Turley, Russell Leek, Cameron Snell, Kevin Gatter, William S. Sly, Richard D. Vaughan-Jones, Pawel Swietach, and Adrian L. Harris

**3112**

The Effects of Chemotherapy on Cognitive Function in a Mouse Model: A Prospective Study

Gordon Winocur, Mark Henkelman, J. Martin Wojtowicz, Haibo Zhang, Malcolm A. Binns, and Ian F. Tannock

**3122**

Dendritic Cell–Activating Vaccine Adjuvants Differ in the Ability to Elicit Antitumor Immunity Due to an Adjuvant-Specific Induction of Immunosuppressive Cells

Yushe Dang, Wolfgang M. Wagner, Ekram Gad, Lauren Rastetter, Carmen M. Berger, Gregory E. Holt, and Mary L. Disis

**IMAGING, DIAGNOSIS, PROGNOSIS**

**3132**

Mutations in the Ras–Raf Axis Underlie the Prognostic Value of CD133 in Colorectal Cancer

Kristel Kemper, Miranda Versloot, Katherine Cameron, Selcuk Colak, Felipe de Sousa e Melo, Joao H. de Jong, Joanne Bleackley, Louis Vermeulen, Rogier Versteeg, Jan Koster, and Jan Paul Medema

**3142**

MSH3 Protein Expression and Nodal Status in MLH1-Deficient Colorectal Cancers

Luigi Laghi, Paolo Bianchi, Gabriele Delconte, Giuseppe Celesti, Giuseppe Di Carlo, Monica Pedroni, Anna Maria Chiaravalli, Barbara Jung, Carlo Capella, Maurizio Ponz de Leon, and Alberto Malesci

**CANCER THERAPY: CLINICAL**

**3154**

SSBP2 Variants Are Associated with Survival in Glioblastoma Patients


**3163**

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer


**3170**

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure


**3180**

Subclinical Peripheral Neuropathy Is a Common Finding in Colorectal Cancer Patients Prior to Chemotherapy

Jessica A. Boyette-Davis, Cathy Eng, Xin S. Wang, Charles S. Cleveland, Gwen Wendelschafer-Crabb, William R. Kennedy, Donald A. Simone, Haijun Zhang, and Patrick M. Dougherty
Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus
Chee Khoo Lee, Ian C. Marschner, R. John Simes, Merryn Voysey, Brian Egleston, Gary Hudes, and Paul de Souza
See commentary p. 2999

Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma
Jean-Pierre Gillet, Anna Maria Calcagno, Sudhir Varma, Ben Davidson, Mari Bunkholt Elstrand, Ram Ganapathi, Aparna A. Kamat, Anil K. Sood, Suresh V. Ambudkar, Michael V. Seiden, Bo R. Rueda, and Michael M. Gottesman

ABOUT THE COVER
Aberrant L1 cell adhesion molecule (LICAM) affects tumor behavior and chemosensitivity in anaplastic thyroid carcinoma (ATC). LICAM is highly expressed in ATC cells, but not in nodular hyperplasia or papillary thyroid carcinoma (PTC) cells. LICAM plays an important role in the aggressiveness of ATC by enhancing proliferation, migration, invasion, and chemoresistance. Photomicrograph showing immunohistochemical staining for LICAM in PTC tissue. 200X magnification. For details, see the article by Kim and colleagues on page 3071 of this issue.
Clinical Cancer Research

18 (11)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/18/11

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.